The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Lenalidomide Causes Selective Degradation of IKZF1 and IKZF3 in Multiple Myeloma Cells
Open accessAbstract
Drug With a (Re)Purpose: Thalidomide, once infamous for its deleterious effects on fetal development, has re-emerged as a drug of great interest because of its beneficial immunomodulatory effects. A derivative drug called lenalidomide significantly extends the survival of patients with multiple myeloma, but the molecular mechanisms underlying its efficacy remain unclear (see the Perspective by Stewart ). Building on a previous observation that thalidomide binds to cereblon, a ubiquitin ligase, Lu et al. (p. 305 , published online 28 November) and Krönke et al. (p. 301 , published online 28 November) show that in the presence of lenalidomide, cereblon selectively targets two B cell transcription factors (Ikaros family members, IKZF1 and IKZF3) for degradation. In myeloma cell lines and patient cells, down-regulation of IKZF1 and IKZF3 was necessary and sufficient for the drug's anticancer activity. Thus, lenalidomide may act, at least in part, by “grepurposing” a ubiquitin ligase.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Thalidomide analogues recruit zinc-finger transcription factors and other targets to CRBN8–11, the substrate receptor of the cullin-RING E3 ubiquitin ligase CUL4A/B-RBX1-DDB1-CRBN (CRL4CRBN)12.”
From The CDK inhibitor CR8 acts as a molecular glue degrader that depletes cyclin K (2020) · cites this paper as [9]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The small molecules thalidomide, lenalidomide, and pomalidomide induce the ubiquitination and proteasomal degradation of the transcription factors Ikaros (IKZF1) and Aiolos (IKZF3) by recruiting a Cys2-His2 (C2H2) zinc finger domain to Cereblon (CRBN), the substrate receptor of the CRL4CRBN E3 ubiquitin ligase.”
From Defining the human C2H2 zinc finger degrome targeted by thalidomide analogs through CRBN (2018) · cites this paper as [3]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Thalidomide analogs bind Cereblon (CRBN), the substrate receptor of the CUL4-RBX1-DDB1-CRBN (CRL4CRBN) E3 ubiquitin ligase and alter its substrate selectivity to recruit, ubiquitinate and degrade seemingly unrelated proteins including Ikaros (IKZF1), Aiolos (IKZF3), Casein kinase 1 alpha (CK1α) and GSPT1 (2–7).”
From Defining the human C2H2 zinc finger degrome targeted by thalidomide analogs through CRBN (2018) · cites this paper as [3]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“proteome-wide mass-spectrometry demonstrated selective degradation of endogenous IKZF1/3, and ZFP91 in multiple cell lines (3, 4, 16).”
From Defining the human C2H2 zinc finger degrome targeted by thalidomide analogs through CRBN (2018) · cites this paper as [3]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Thalidomide, lenalidomide and pomalidomide mediate CRL4CRBN-dependent degradation of a larger number of proteins than previously appreciated through a C2H2 ZF degron (3, 4, 16).”
From Defining the human C2H2 zinc finger degrome targeted by thalidomide analogs through CRBN (2018) · cites this paper as [3]
Experimental — accuracy not yet measured
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“their recruitment to cRl4 cRBN , upon lenalidomide treatment, led to their selective ubiquitylation and proteasomal degradation, ablating their role at promoters of their target genes (Krönke et al. 2014;lu et al. 2014).”
From From serendipity to strategy: molecular glue degraders in cancer therapeutics (2025) · cites this paper as Krönke et al. 2014
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Both thalidomide and lenalidomide lack specificity for iKZF2 (Krönke et al. 2014;lu et al. 2014), as it encodes a histidine in a critical thalidomidebinding position.”
From From serendipity to strategy: molecular glue degraders in cancer therapeutics (2025) · cites this paper as Krönke et al. 2014
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Mechanistic studies later confirmed that the efficacy of lenalidomide in 5q-MDS was actually due to the recruitment of an unexpected neo-substrate: the kinase cK1α (CSNK1A1) which resides within the long arm of chromosome 5 (5q32) (Krönke et al. 2014) (Figure 5B, i).”
From From serendipity to strategy: molecular glue degraders in cancer therapeutics (2025) · cites this paper as Krönke et al. 2014
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“IMiDs bind to cereblon and activate cereblon E3 ligase activity, resulting in the rapid ubiquitination and degradation of two specific B cell transcription factors, Ikaros family zinc finger proteins Ikaros (IKZF 1) and Aiolos (IKZF3).77–79”
From Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management (2024) · cites this paper as [78]
The cited source says what the claim attributes to it.
In the citing paper
“These drugs co-opt CRBN to target IKAROS family zinc finger 1 (IKZF1) and IKZF3 for degradation3,4,24, and are now considered as pioneering examples of molecular glues.”
From PROTAC targeted protein degraders: the past is prologue (2022) · cites this paper as [4]
The cited source says what the claim attributes to it.
In the citing paper
“lenalidomide was shown to promote the interaction between cRBN and two members of the ikaros transcription factor family: iKZF1 and iKZF3 (gandhi et al. 2014;Krönke et al. 2014;lu et al. 2014).”
From From serendipity to strategy: molecular glue degraders in cancer therapeutics (2025) · cites this paper as Krönke et al. 2014
The cited source says what the claim attributes to it.
In the citing paper
“As such, lenalidomide can promote the interaction between cRl4 cRBN and both iKZF1 and iKZF3 resulting in their selective degradation which disrupts their role at gene promoters (Krönke et al. 2014;lu et al. 2014).”
From From serendipity to strategy: molecular glue degraders in cancer therapeutics (2025) · cites this paper as Krönke et al. 2014
In the citing paper
“These compounds, collectively known as immunomodulatory drugs (IMiDs), can promote the degradation of a host of cellular proteins by extending the subpar interfaces they form with CRBN, the substrate receptor of the CUL4-RBX1-DDB1 (CRL4) ubiquitin ligase complex9–20.”
From Defining molecular glues with a dual-nanobody cannabidiol sensor (2022) · cites this paper as [10]
In the citing paper
“As described before, in the presence of IMiDs, CRBN E3 ligase induces the proteasomal degradation of a set neo-substrates, such as IKZF1/3[13,39], CK1α[40] and GSPT1[15].”
From Development of MDM2 degraders based on ligands derived from Ugi reactions: Lessons and discoveries (2021) · cites this paper as [13]
In the citing paper
“This is further supported by the observations that PZ could selectively induce Bcl-xl but not Bcl-2 poly-ubiquitination and had no significant effect on the expression of the CRBN native substrate, glutamine synthetase (GS)36, and its neosubstrates recruited by thalidomide and its analogues including CK1α37, IKZF1, and IKZF3 (ref. 38) (Supplementary Fig. 1 f, g).”
From Using proteolysis-targeting chimera technology to reduce navitoclax platelet toxicity and improve its senolytic activity (2020) · cites this paper as [38]
In the citing paper
“In brief, IMiDs bind the E3 ligase cereblon (CRBN), thus complementing a surface patch that subsequently recruits a variety of C2H2 zinc finger transcription factors for ubiquitination and degradation.48−51”
From Advancing Targeted Protein Degradation via Multiomics Profiling and Artificial Intelligence (2023) · cites this paper as [50]
In the citing paper
“In brief, IMiDs were first shown to trigger CRBN-dependent proteasomal degradation of the C2H2-type zing-finger transcription factors Ikaros (IKZF1) and Aiolos (IKZF3).[46][47][48]”
From Chasing molecular glue degraders: screening approaches (2022) · cites this paper as [47]
In the citing paper
“The presence of a glutamine residue in their second zing-finger domain enables IMiD-induced degradation, 47 while the histidine residues in Helios (IKZF2) do not.”
From Chasing molecular glue degraders: screening approaches (2022) · cites this paper as [47]
In the citing paper
“thalidomide interacts with CRBN to form a novel surface, resulting in interactions with neosubstrates such as Ikaros (IKZF1) and Aiolos (IKZF3) and their ubiquitination and subsequent proteasomal degradation.20,21”
From Bruton tyrosine kinase degradation as a therapeutic strategy for cancer (2019) · cites this paper as [20]
In the citing paper
“lenalidomide and pomalidomide induce CRBN-dependent ubiquitination and degradation of Ikaros and Aiolos, transcription factors required for the development of lymphoids and survival of multiple myeloma8–10.”
From Genome-wide screening reveals a role for subcellular localization of CRBN in the anti-myeloma activity of pomalidomide (2020) · cites this paper as [8]
In the citing paper
“Molecular glues, based on the serendipitous discovery that thalidomide and its analogues act as degrader molecules, constitute another important therapeutic class1–8.”
From PROTAC targeted protein degraders: the past is prologue (2022) · cites this paper as [4]
In the citing paper
“CRBN appears to be emerging as a preferred E3 ligase for the first wave of TPD therapeutics in clinical trials.”
From PROTAC targeted protein degraders: the past is prologue (2022) · cites this paper as [4]
In the citing paper
“Examples here include the approved IMiD class, which relies on CRBN to degrade IKZF1/IKZF3 (refs4,5) via a molecular glue mechanism”
From PROTAC targeted protein degraders: the past is prologue (2022) · cites this paper as [4]
In the citing paper
“thalidomide and its analogues do not inhibit the enzymatic activity of CRL4CRBN, but instead confer neomorphic activity on CRBN to mediate the selective ubiquitination and resultant proteasomal degradation of the transcription factors Ikaros family zinc finger protein 1 (IKZF1) and IKZF3 (Aiolos) in MM cells and T cells11–13.”
From Cancer therapies based on targeted protein degradation — lessons learned with lenalidomide (2021) · cites this paper as [11]
In the citing paper
“In 2013, thalidomide analogues were discovered to exert their therapeutic effects by acting as a molecular glue to recruit disease-relevant neosubstrate proteins to an E3 ubiquitin ligase, resulting in neosubstrate ubiquitination and, ultimately, proteasomal degradation11–13.”
From Cancer therapies based on targeted protein degradation — lessons learned with lenalidomide (2021) · cites this paper as [11]
In the citing paper
“given that proteasome inhibitors antagonize lenalidomide-induced protein degradation11,12,55.”
From Cancer therapies based on targeted protein degradation — lessons learned with lenalidomide (2021) · cites this paper as [11]
In the citing paper
“Most known neosubstrate proteins have been identified through proteomic analyses of different cell lineages11,15,165,166.”
From Cancer therapies based on targeted protein degradation — lessons learned with lenalidomide (2021) · cites this paper as [11]
In the citing paper
“Ebert's gourp and Kaelin Jr's group independently demonstrated that when lenalidomide binds to CRBN, a new function of CRBN is induced, namely, to ubiquitinate and degrade Ikaros (IKZF1) and Aiolos (IKZF3), which are transcription factors that are known to be responsible for the maturation of B cells [25,26].”
From Cereblon and its downstream substrates as molecular targets of immunomodulatory drugs (2016) · cites this paper as [25]
In the citing paper
“CRBN was shown to bind the drug thalidomide in its substrate binding pocket, thereby creating a new surface to recruit other proteins for ubiquitination and degradation, such as the transcription factors Ikaros and Aiolos (IKZF1 and 3, respectively) or the kinase CK1α [70–72].”
From Advances in targeted degradation of endogenous proteins (2019) · cites this paper as [72]
In the citing paper
“The clinical efficacy of IMiDs is driven at least in part by their capacity to induce CRBN-mediated degradation of neo-substrates: cancer cells become resistant to the multiple myeloma IMiD drug lenalidomide upon mutation of a single amino acid in IKFZ3 that rescues this transcription factor from proteolytic degradation 7 ;”
From Targeted protein degradation: expanding the toolbox (2019) · cites this paper as [7]
In the citing paper
“cancer cells become resistant to the multiple myeloma IMiD drug lenalidomide upon mutation of a single amino acid in IKFZ3 that rescues this transcription factor from proteolytic degradation 7 ;”
From Targeted protein degradation: expanding the toolbox (2019) · cites this paper as [7]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rappsilber, J., Mann, M., & Ishihama, Y. (2007) · Nature Protocols · doi:10.1038/nprot.2007.261 · Cited by 4,641
RING Domain E3 Ubiquitin Ligases
Deshaies, R. J., & Joazeiro, C. A. P. (2009) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.78.101807.093809 · Cited by 2,679
Identification of a Primary Target of Thalidomide Teratogenicity
Ito, T., Ando, H., Suzuki, T., Ogura, T., Hotta, K., Imamura, Y., Yamaguchi, Y., & Handa, H. (2010) · Science · doi:10.1126/science.1177319 · Cited by 2,136
An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer
Soucy, T. A., Smith, P. G., Milhollen, M. A., Berger, A. J., Gavin, J. M., Adhikari, S., Brownell, J. E., Burke, K. E., Cardin, D. P., Critchley, S., et al. (2009) · Nature · doi:10.1038/nature07884 · Cited by 1,990
Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia
Mullighan, C. G., Goorha, S., Radtke, I., Miller, C. B., Coustan‐Smith, E., Dalton, J., Girtman, K., Mathew, S., Ma, J., Pounds, S. B., et al. (2007) · Nature · doi:10.1038/nature05690 · Cited by 1,777
Mechanism of auxin perception by the TIR1 ubiquitin ligase
Tan, X., Calderon-Villalobos, L. I. A., Sharon, M., Zheng, C., Robinson, C. V., Estelle, M., & Zheng, N. (2007) · Nature · doi:10.1038/nature05731 · Cited by 1,688
Sampaio, E. P., Sarno, E. N., Gallily, R., Cohn, Z. A., & Kaplan, G. (1991) · The Journal of Experimental Medicine · doi:10.1084/jem.173.3.699 · Cited by 1,191
The ikaros gene is required for the development of all lymphoid lineages
Georgopoulos, K., Bigby, M., Wang, J.-H., Molnar, A., Wu, P., Winandy, S., & Sharpe, A. (1994) · Cell · doi:10.1016/0092-8674(94)90407-3 · Cited by 985
A practical recipe for stable isotope labeling by amino acids in cell culture (SILAC)
Ong, S., & Mann, M. (2006) · Nature Protocols · doi:10.1038/nprot.2006.427 · Cited by 917
Lopez-Girona, A., Mendy, D., Ito, T., Miller, K., Gandhi, A. K., Kang, J., Karasawa, S., Carmel, G., Jackson, P., Abbasian, M., et al. (2012) · Leukemia · doi:10.1038/leu.2012.119 · Cited by 814
Cited by
Sorted by citations
Items 701–800 of 1,006
Covalent Degrader of the Oncogenic Transcription Factor β-Catenin
Gowans, F. A., Forte, N., Hatcher, J., Huang, O. W., Wang, Y., Poblano, B. E. A., Wertz, I. E., & Nomura, D. K. (2024) · Journal of the American Chemical Society · doi:10.1021/jacs.4c05174 · Cited by 30
A FRET-Based Assay for the Identification and Characterization of Cereblon Ligands
Boichenko, I., Deiss, S., Bär, K., Hartmann, M. D., & Alvarez, B. H. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b01735 · Cited by 30
Amengual, J. E., Prabhu, S. A., Lombardo, M., Zullo, K. M., Johannet, P. M., Gonzalez, Y., Scotto, L., Serrano, X. O. J., Wei, Y., Duong, J., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2022 · Cited by 28
Hou, L., Zhao, J., Gao, S., Ji, T., Song, T., Li, Y., Wang, J., Geng, C., Long, M., Chen, J., et al. (2019) · Science Advances · doi:10.1126/sciadv.aau7130 · Cited by 32
Patel, V. G., & Cornell, R. F. (2019) · Current Oncology Reports · doi:10.1007/s11912-019-0784-4 · Cited by 28
Cullin 4-DCAF Proteins in Tumorigenesis
Zhou, Z., Song, X., Wavelet, C. M., & Wan, Y. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-981-15-1025-0_15 · Cited by 29
Targeting the E3 ubiquitin ligases DCAF15 and cereblon for cancer therapy
Nguyen, K. M., & Busino, L. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.03.007 · Cited by 29
Beedie, S., Huang, P. A., Harris, E. M., Strope, J. D., Mahony, C. B., Chau, C. H., Vargesson, N., & Figg, W. D. (2020) · The FASEB Journal · doi:10.1096/fj.201903060rr · Cited by 28
The application of ubiquitin ligases in the PROTAC drug design
Chen, Y., & Jin, J. (2020) · Acta Biochimica et Biophysica Sinica · doi:10.1093/abbs/gmaa053 · Cited by 29
Ye, Y., Gaudy, A. M., Schafer, P. H., Thomas, M. A., Weiss, D., Chen, N., Liu, L., Xue, Y., Carayannopoulos, L. N., & Palmisano, M. (2020) · Clinical Pharmacology in Drug Development · doi:10.1002/cpdd.869 · Cited by 27
Charliński, G., Vesole, D. H., & Jurczyszyn, A. J. (2021) · Cancers · doi:10.3390/cancers13184666 · Cited by 31
Molecular Mechanisms of Cereblon-Interacting Small Molecules in Multiple Myeloma Therapy
Costacurta, M., He, J., Thompson, P. E., & Shortt, J. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11111185 · Cited by 27
Dissecting and targeting noncanonical functions of EZH2 in multiple myeloma via an EZH2 degrader
Yu, X., Wang, J., Gong, W., Ma, A., Shen, Y., Zhang, C., Liu, X., Cai, L., Liu, J., Wang, G. G., et al. (2023) · Oncogene · doi:10.1038/s41388-023-02618-5 · Cited by 28
Targeted therapy for fusion-driven high-risk acute leukemia
Pikman, Y., & Stegmaier, K. (2018) · Blood · doi:10.1182/blood-2018-04-784157 · Cited by 29
Taming the Heterogeneity of Aggressive Lymphomas for Precision Therapy
Young, R. M., Phelan, J. D., Shaffer, A. L., Wright, G. W., Huang, D. W., Schmitz, R., Johnson, C. A., Oellerich, T., Wilson, W. H., & Staudt, L. M. (2018) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-030518-055734 · Cited by 27
Mostofa, A., Distler, A., Meads, M. B., Sahakian, E., Powers, J. J., Achille, A., Noyes, D., Wright, G., Fang, B., Izumi, V., et al. (2021) · JCI Insight · doi:10.1172/jci.insight.151713 · Cited by 27
Targeted protein degradation as an antiviral approach
Chakravarty, A., & Yang, P. L. (2022) · Antiviral Research · doi:10.1016/j.antiviral.2022.105480 · Cited by 28
Feng, Y., Hu, X., & Wang, X. (2024) · Biomarker Research · doi:10.1186/s40364-024-00638-1 · Cited by 30
PROTAC unleashed: Unveiling the synthetic approaches and potential therapeutic applications
Pravin, N., & Jóźwiak, K. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116837 · Cited by 29
Distinct landscape and clinical implications of therapy-related clonal hematopoiesis
Takahashi, K., Nakada, D., & Goodell, M. A. (2024) · Journal of Clinical Investigation · doi:10.1172/jci180069 · Cited by 32
Immunomodulatory drugs in AL amyloidosis
Jelı́nek, T., Kufova, Z., & Hájek, R. (2016) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2016.01.004 · Cited by 27
Biology of CNS lymphoma and the potential of novel agents
Rubenstein, J. L. (2017) · Hematology · doi:10.1182/asheducation-2017.1.556 · Cited by 27
Eichner, R., Fernández‐Sáiz, V., Targosz, B., & Bassermann, F. C. (2018) · International review of cytology · doi:10.1016/bs.ircmb.2018.06.001 · Cited by 27
Emerging modes-of-action in drug discovery
Valeur, E., Narjes, F., Ottmann, C., & Plowright, A. T. (2019) · MedChemComm · doi:10.1039/c9md00263d · Cited by 29
Tachita, T., Kinoshita, S., Ri, M., Aoki, S., Asano, A. T., Kanamori, T., Yoshida, T., Totani, H., Ito, A., Kusumoto, S., et al. (2020) · Cancer Science · doi:10.1111/cas.14352 · Cited by 27
The Role of Cullin-RING Ligases in Striated Muscle Development, Function, and Disease
Blondelle, J., Biju, A., & Lange, S. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21217936 · Cited by 27
Misiewicz-Krzemińska, I., Ramón, C. D., Corchete, L. A., Krzemiński, P., Rojas, E. A., Isidro, I. M., García‐Sánz, R., Martínez‐López, J., Oriol, A., Bladé, J., et al. (2020) · Blood Advances · doi:10.1182/bloodadvances.2020002711 · Cited by 27
Jakobsen, T., Dahl, M., Dimopoulos, K., Grønbæk, K., Kjems, J., & Kristensen, L. S. (2021) · Cancers · doi:10.3390/cancers13030365 · Cited by 28
Selective degradation-inducing probes for studying cereblon (CRBN) biology
Powell, C. E., Du, G., Bushman, J. W., He, Z., Zhang, T., Fischer, E. S., & Gray, N. S. (2021) · RSC Medicinal Chemistry · doi:10.1039/d0md00382d · Cited by 29
Redefining CD56 as a Biomarker and Therapeutic Target in Multiple Myeloma
Cottini, F., Rodriguez, J., Hughes, T., Sharma, N., Guo, L., Lozanski, G., Liu, B., Cocucci, E., Yang, Y., & Benson, D. (2022) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-21-0828 · Cited by 30
Past, Present, and a Glance into the Future of Multiple Myeloma Treatment
Elbezanti, W. O., Challagundla, K. B., Jonnalagadda, S. C., Budak-Alpdoǧan, T., & Pandey, M. K. (2023) · Pharmaceuticals · doi:10.3390/ph16030415 · Cited by 36
Protein ubiquitination in lymphoid malignancies
Yang, Y., & Staudt, L. M. (2014) · Immunological Reviews · doi:10.1111/imr.12247 · Cited by 27
Novel Agents in Multiple Myeloma
Szalat, R. E., & Munshi, N. C. (2019) · The Cancer Journal · doi:10.1097/ppo.0000000000000355 · Cited by 27
Self-citationPintacuda, G., Lassen, F. H., Hsu, Y.-H. H., Kim, A., Martín, J. M., Małolepsza, E., Lim, J., Fornelos, N., Eggan, K. C., & Lage, K. (2021) · Nature Communications · doi:10.1038/s41467-021-22648-5 · Cited by 24
The characteristics of FBXO7 and its role in human diseases
Zhong, Y., Li, J., Ye, M., & Jin, X. (2022) · Gene · doi:10.1016/j.gene.2022.146972 · Cited by 25
Breaking Bad Proteins—Discovery Approaches and the Road to Clinic for Degraders
Bouvier, C., Lawrence, R., Cavallo, F., Xolalpa, W., Jordan, A. M., Hjerpe, R., & Rodríguez, M. S. (2024) · Cells · doi:10.3390/cells13070578 · Cited by 28
Lin, J., Chen, Z., Zhang, D., Zhang, N., Chen, H., & Guo, D. (2025) · Macromolecular Rapid Communications · doi:10.1002/marc.202401051 · Cited by 28
Chen, Z., Dhruv, H., Zhang, X., Rej, R. K., Bai, L., McEachern, D., Kirchhoff, P. D., Nagilla, R., Jolivette, L. J., Rice, C., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-58431-z · Cited by 28
Medicinal Chemistry of Inhibiting RING-Type E3 Ubiquitin Ligases
Blaquière, N., Villemure, E., & Staben, S. T. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b01451 · Cited by 26
ERK signaling mediates resistance to immunomodulatory drugs in the bone marrow microenvironment
Liu, J., Hideshima, T., Xing, L., Wang, S., Zhou, W., Samur, M., Sewastianik, T., Ogiya, D., An, G., Gao, S., et al. (2021) · Science Advances · doi:10.1126/sciadv.abg2697 · Cited by 27
Self-citationTargeted Therapies and Immune Checkpoint Inhibitors in Primary CNS Lymphoma
Wirsching, H., Weller, M., Balabanov, S., & Roth, P. (2021) · Cancers · doi:10.3390/cancers13123073 · Cited by 26
Lü, J., Jiang, H., Li, D., Chen, T., Wang, Y., Pu, Z., & Xu, G. (2021) · Journal of Proteome Research · doi:10.1021/acs.jproteome.1c00437 · Cited by 26
Guenther, C., Faisal, I., Fusciello, M., Sokolova, M., Harjunpää, H., Ilander, M. M., Tallberg, R., Vartiainen, M. K., Alon, R., González, J. M., et al. (2021) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-21-0094 · Cited by 26
Roles of Cullin-RING Ubiquitin Ligases in Cardiovascular Diseases
Diaz, S., Wang, K., Sjögren, B., & Liu, X. (2022) · Biomolecules · doi:10.3390/biom12030416 · Cited by 27
Zhang, T., Wang, Y., Wang, B., Jin, W., Xia, Y., Liu, C., & Zhang, Y. (2022) · Advanced Synthesis & Catalysis · doi:10.1002/adsc.202101506 · Cited by 26
Geyer, M. B., Shaffer, B. C., Bhatnagar, B., Mims, A. S., Klein, V., Dilip, D., Glass, J. L., Lozanski, G., Hassoun, H., Landau, H. J., et al. (2023) · Blood Advances · doi:10.1182/bloodadvances.2022009212 · Cited by 26
The role of E3 ubiquitin ligases in bone homeostasis and related diseases
Dong, Y., Chen, Y., Ma, G., & Cao, H. (2023) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2023.06.016 · Cited by 26
Targeting mutant p53 through the mevalonate pathway
Freed-Pastor, W. A., & Prives, C. L. (2016) · Nature Cell Biology · doi:10.1038/ncb3435 · Cited by 27
Mechanisms of Resistance in Multiple Myeloma
Papadas, A., & Asimakopoulos, F. A. (2017) · Handbook of experimental pharmacology · doi:10.1007/164_2017_10 · Cited by 26
Unleashing the power of NK cells in anticancer immunotherapy
Vogler, M., Shanmugalingam, S., Särchen, V., Reindl, L. M., Grèze, V., Buchinger, L., Kühn, M. W. M., & Ullrich, E. (2021) · Journal of Molecular Medicine · doi:10.1007/s00109-021-02120-z · Cited by 28
Degradome analysis to identify direct protein substrates of small-molecule degraders
Jochem, M., Schrempf, A., Wagner, L.-M., Segal, D., Cisneros, J., Ng, A., Winter, G. E., & Krijgsveld, J. (2025) · Cell Chemical Biology · doi:10.1016/j.chembiol.2024.10.007 · Cited by 25
Aiolos collaborates with Blimp-1 to regulate the survival of multiple myeloma cells
Hung, K.-H., Su, S.-T., Chen, C.-Y., Hsu, P.-H., Huang, S.-Y., Wu, W.-J. H., Chen, M.-J. M., Chen, H.-Y., Wu, P.-C., Lin, F.-R., et al. (2016) · Cell Death and Differentiation · doi:10.1038/cdd.2015.167 · Cited by 25
Ubiquitin-dependent proteasomal degradation of AMPK gamma subunit by Cereblon inhibits AMPK activity
Yang, S., Jeon, S., Nguyen, T. V., Deshaies, R. J., Park, C., & Lee, K. M. (2020) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2020.118729 · Cited by 26
Fu, S.-J., Hu, M., Peng, Y.-J., Fang, H.-Y., Hsiao, C.-T., Chen, T., Jeng, C., & Tang, C. (2020) · Cells · doi:10.3390/cells9061332 · Cited by 25
Loss of 5q in myeloid malignancies – A gain in understanding of biological and clinical consequences
Venugopal, S., Mascarenhas, J. O., & Steensma, D. P. (2020) · Blood Reviews · doi:10.1016/j.blre.2020.100735 · Cited by 26
A Journey Through Myeloma Evolution: From the Normal Plasma Cell to Disease Complexity
Vià, M. D., Ziccheddu, B., Maeda, A., Bagnoli, F., Perrone, G., & Bolli, N. (2020) · HemaSphere · doi:10.1097/hs9.0000000000000502 · Cited by 27
Sweet and Blind Spots in E3 Ligase Ligand Space Revealed by a Thermophoresis-Based Assay
Maiwald, S. A., Heim, C., Alvarez, B. H., & Hartmann, M. D. (2020) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.0c00440 · Cited by 26
Perner, F., & Armstrong, S. A. (2020) · Cells · doi:10.3390/cells9122721 · Cited by 25
Rivellese, F., Manou-Stathopoulou, S., Mauro, D., Goldmann, K., Pyne, D., Rajakariar, R., Gordon, P., Schafer, P. H., Bombardieri, M., Pitzalis, C., et al. (2021) · Lupus Science & Medicine · doi:10.1136/lupus-2020-000445 · Cited by 25
CD4 + T cells require Ikaros to inhibit their differentiation toward a pathogenic cell fate
Bernardi, C., Maurer, G., Ye, T., Marchal, P., Jost, B., Wissler, M., Maurer, U., Kastner, P., Chan, S. H., & Charvet, C. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2023172118 · Cited by 25
Uehling, D., Joseph, B., Chung, K. C., Zhang, A. X., Ler, S., Prakesch, M. A., Poda, G. I., Grouleff, J., Aman, A. M., Kiyota, T., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00506 · Cited by 24
Automating UbiFast for High-throughput and Multiplexed Ubiquitin Enrichment
Rivera, K. D., Olive, M. E., Bergstrom, E. J., Nelson, A. J., Lee, K. A., Satpathy, S., Carr, S. A., & Udeshi, N. D. (2021) · Molecular & Cellular Proteomics · doi:10.1016/j.mcpro.2021.100154 · Cited by 26
Self-citationAdvances in the Design and Development of PROTAC-mediated HDAC Degradation
Rodrigues, D. A., Roe, A. J., Griffith, D. M., & Chonghaile, T. N. (2021) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026621666211015092047 · Cited by 27
Takwale, A. D., Kim, E. Y., Jang, Y., Lee, D.-H., Kim, S., Choi, Y., Kim, J. H., Lee, D. Y., Kim, Y., Lee, S. M., et al. (2022) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2022.105923 · Cited by 25
Kulig, P., Milczarek, S., Bakinowska, E., Szalewska, L., Baumert, B., & Machaliński, B. (2023) · Cancers · doi:10.3390/cancers15030963 · Cited by 26
IKAROS: a multifunctional regulator of the polymerase II transcription cycle
Bottardi, S., Mavoungou, L. O., & Milot, É. (2015) · Trends in Genetics · doi:10.1016/j.tig.2015.05.003 · Cited by 25
Blaes, A. H., Thavendiranathan, P., & Moslehi, J. J. (2018) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_208509 · Cited by 25
Treatment of Lymphoid and Myeloid Malignancies by Immunomodulatory Drugs
Fuchs, O. (2018) · Cardiovascular & Haematological Disorders - Drug Targets · doi:10.2174/1871529x18666180522073855 · Cited by 26
Pourabdollah, M., Bahmanyar, M., Atenafu, E. G., Reece, D., Hou, J., & Chang, H. (2016) · Journal of Hematology & Oncology · doi:10.1186/s13045-016-0354-2 · Cited by 24
A New Generation of IMiDs as Treatments for Neuroinflammatory and Neurodegenerative Disorders
Kopp, K. O., Greer, M. E., Glotfelty, E. J., Hsueh, S., Tweedie, D., Kim, D. S., Reale, M., Vargesson, N., & Greig, N. H. (2023) · Biomolecules · doi:10.3390/biom13050747 · Cited by 26
Dual-site molecular glues for enhancing protein-protein interactions of the CDK12-DDB1 complex
Zhang, Z., Li, Y., Yang, J., Li, J., Lin, X., Liu, T., Yang, S., Lin, J., Xue, S., Yu, J., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-50642-0 · Cited by 27
The von Hippel–Lindau Tumor Suppressor Protein
Kaelin, W. G. (2018) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-030617-050527 · Cited by 24
Spironolactone‐induced XPB degradation depends on CDK7 kinase and SCFFBXL18 E3 ligase
Ueda, M., Matsuura, K., Kawai, H., Wakasugi, M., & Matsunaga, T. (2019) · Genes to Cells · doi:10.1111/gtc.12674 · Cited by 26
McCaughan, G. J. B., Gandolfi, S., Moore, J. J., & Richardson, P. G. G. (2022) · British Journal of Haematology · doi:10.1111/bjh.18295 · Cited by 26
Immunostimulatory Gene Therapy Using Oncolytic Viruses as Vehicles
Loskog, A. (2015) · Viruses · doi:10.3390/v7112899 · Cited by 24
Immune checkpoint blockade in lymphoid malignancies
Thanarajasingam, G., Thanarajasingam, U., & Ansell, S. M. (2016) · FEBS Journal · doi:10.1111/febs.13668 · Cited by 24
Lenalidomide for the treatment of B-cell lymphoma
Garciaz, S., Coso, D., de Colella, J. S., & Bouabdallah, R. (2016) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2016.1208170 · Cited by 24
Recent advances in understanding multiple myeloma
Dhakal, B., Girnius, S. K., & Hari, P. (2016) · F1000Research · doi:10.12688/f1000research.8777.1 · Cited by 25
Awwad, M. H. S., Kriegsmann, K., Plaumann, J., Benn, M., Hillengaß, J., Raab, M. S., Bertsch, U., Munder, M., Weisel, K. C., Salwender, H. J., et al. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1486356 · Cited by 26
Targeted protein degradation in antibacterial drug discovery?
Gopal, P., & Dick, T. (2019) · Progress in Biophysics and Molecular Biology · doi:10.1016/j.pbiomolbio.2019.11.005 · Cited by 24
Immunoproteasome Function in Normal and Malignant Hematopoiesis
Santamaría, N. T., Ebstein, F., Heidel, F. H., & Krüger, E. (2021) · Cells · doi:10.3390/cells10071577 · Cited by 25
Keeping Myeloma in Check: The Past, Present and Future of Immunotherapy in Multiple Myeloma
Ackley, J. C., Ochoa, M. A., Ghoshal, D., Roy, K., Lonial, S., & Boise, L. (2021) · Cancers · doi:10.3390/cancers13194787 · Cited by 25
Miguel, J. F. S., Einsele, H., & Moreau, P. (2016) · Advances in Therapy · doi:10.1007/s12325-016-0413-7 · Cited by 25
Amatangelo, M. D., Flynt, E., Stong, N., Ray, P. R., Oekelen, O. V., Wang, M., Ortiz, M., Maciag, P., Peluso, T., Parekh, S. S., et al. (2024) · Cell Reports Medicine · doi:10.1016/j.xcrm.2024.101571 · Cited by 23
Anaya, Y. A., Barragan, M., Bracho, R. P., Shaham, S. H., Bandyopadhyay, D., George, E., Nguyen, D. D. T., & Tripathi, M. K. (2025) · Cancer · doi:10.1002/cncr.70132 · Cited by 26
Multiple Myeloma: What Do We Do About Immunodeficiency?
Li, L., & Wang, L. (2019) · Journal of Cancer · doi:10.7150/jca.29993 · Cited by 23
Jeng, C., Fu, S.-J., You, C.-Y., Peng, Y.-J., Hsiao, C.-T., Chen, T., & Tang, C. (2020) · Frontiers in Neurology · doi:10.3389/fneur.2020.00076 · Cited by 22
Jones, J. R., Barber, A., Bihan, Y. L., Weinhold, N., Ashby, C., Walker, B. A., Wardell, C. P., Wang, H., Kaiser, M., Jackson, G. H., et al. (2021) · Leukemia · doi:10.1038/s41375-021-01373-4 · Cited by 24
Emerging approaches to CDK inhibitor development, a structural perspective
Hope, I., Endicott, J., & Watt, J. E. (2022) · RSC Chemical Biology · doi:10.1039/d2cb00201a · Cited by 22
Human and mouse early B cell development: So similar but so different
Korzhenevich, J., Janowska, I., van der Burg, M., & Rizzi, M. (2023) · Immunology Letters · doi:10.1016/j.imlet.2023.07.004 · Cited by 23
Reddy, N. M., & Thiéblemont, C. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx358 · Cited by 22
Anti-cancer vaccine therapy for hematologic malignancies: An evolving era
Nahas, M. R., Rosenblatt, J. M., Lazarus, H. M., & Avigan, D. (2018) · Blood Reviews · doi:10.1016/j.blre.2018.02.002 · Cited by 23
Liu, A., Li, S., Donnenberg, V. S., Fu, J., Gollin, S. M., Ma, H., Lu, C., Stolz, D. B., Mapara, M. Y., Monaghan, S. A., et al. (2018) · Haematologica · doi:10.3324/haematol.2018.188227 · Cited by 25
Rojas, E. A., Corchete, L. A., Mateos, M., García‐Sánz, R., Misiewicz-Krzemińska, I., & Gutierrez, N. C. (2019) · Blood Cancer Journal · doi:10.1038/s41408-019-0253-1 · Cited by 23
Zhou, B., Jin, X.-H., Jin, W., Huang, X., Wu, Y.-F., Li, H.-Y., Zhu, W., Qin, X., Ye, H.-G., & Gao, S.-M. (2020) · Journal of Translational Medicine · doi:10.1186/s12967-020-02384-y · Cited by 27
Tong, K. I., Yoon, S., Isaev, K., Bakhtiari, M., Lackraj, T., He, M. Y., Joynt, J., Silva, A., Xu, M. C., Privé, G. G., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-4027 · Cited by 24
Raje, N. S., Hideshima, T., Yee, A. J., & Anderson, K. C. (2017) · Wiley eBooks · doi:10.1002/9781119000822.hfcm122 · Cited by 23
Crbn-based molecular Glues: Breakthroughs and perspectives
An, J., & Zhang, X. (2024) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2024.117683 · Cited by 22
Oekelen, O. V., Amatangelo, M. D., Guo, M., Upadhyaya, B., Cribbs, A. P., Kelly, G., Patel, M., Kim‐Schulze, S., Flynt, E., Laganà, A., et al. (2024) · Cell Reports Medicine · doi:10.1016/j.xcrm.2024.101584 · Cited by 25
Blanquart, E., Ekren, R., Rigaud, B., Joubert, M.-V., Baylot, V., Daunes, H., Cuisinier, M., Villard, M., Carrié, N., Mazzotti, C., et al. (2024) · Blood · doi:10.1182/blood.2023023529 · Cited by 26
Metadata
- Authors
- Krönke, J., Udeshi, N. D., Narla, A., Grauman, P., Hurst, S. N., McConkey, M., Svinkina, T., Heckl, D., Comer, E., Li, X., Ciarlo, C., Hartman, E., Munshi, N., Schenone, M., Schreiber, S. L., Carr, S. A., & Ebert, B. L.
- Affiliations
- Brigham and Women's Hospital (US)
- Broad Institute (US)
- Dana-Farber Cancer Institute (US)
- Corresponding author
- Ebert, Benjamin L.
- ORCID
- Venue
- Science
- Published
- 2014-01-17
- Volume
- 343
- Issue
- 6168
- Pages
- 301-305
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- PMC
- PMC4077049
- OpenAlex
- W2015345028
- Semantic Scholar
- bf4fc60d821257f664ef758f219b75586ad0adaa
- Cited by
- 1,879
- References
- 31
- Citations by year
- 2026: 159 · 2025: 188 · 2024: 185 · 2023: 169 · 2022: 176 · 2021: 196 · 2020: 186 · 2019: 138 · 2018: 125 · 2017: 100 · 2016: 102 · 2015: 88 · 2014: 59
- FWCI
- 37.61
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Deutsche Forschungsgemeinschaft
- National Institutes of Health (5p01ca078378-15)
- National Heart, Lung, and Blood Institute (R01HL082945)
- National Human Genome Research Institute (RL1HG004671)
- National Cancer Institute (P01-CA078378, P50CA100707, P01CA108631, P01CA155258)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
- Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Ubiquitin and proteasome pathways
- Keywords
- lenalidomide, multiple myeloma, IKZF1, IKZF3, selective protein degradation, E3 ubiquitin ligase, ubiquitination, mechanism of action, IL-2 production, T cells, transcription factors
- MeSH terms
- Lenalidomide, Antineoplastic Agents, Humans, Interleukin-2, Multiple Myeloma, T-Lymphocytes, Thalidomide, Cell Line, Tumor, Ikaros Transcription Factor, Ubiquitination, HEK293 Cells, Proteolysis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
